Research Impact

h-index

N/A

Research impact score

Publications

0

Total publications

Trial Results

0

Published trial results

Citations

0

Total citations

Drug Portfolio

Analytics

Trial Phases

Phase 22

Trial Status

Completed1
Other2

Role Distribution

Principal Investigator3
PI Rate100%

Activity Timeline

Clinical Trials (3)

NCT01639521Phase 2Withdrawn
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
Anterior Urethral CancerLocalized Transitional Cell Cancer of the Renal Pelvis and UreterPosterior Urethral Cancer+7 more
Principalinvestigator
NCT01685125Phase 2Unknown
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Principalinvestigator
NCT02237612Not ApplicableCompleted
Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer
Adenocarcinoma of the ProstateStage IIA Prostate CancerStage IIB Prostate Cancer
Principalinvestigator

Research Network

Collaboration Network

1 collaborators·0 connections
Network Legend
KOL
Current Investigator
CO
High-influence Collaborator
CO
Collaborator
Click: view details
Double-click: go to profile
Drag: move node

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Jacek Pinski

University of Southern California

Related
4 trials

Shared therapeutic areas:

Hormone-Resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer+3 more

Worked with same sponsors:

National Cancer Institute (NCI)University of Southern California
Similarity Score11%

Betty Ferrell

City of Hope Medical Center

Related
5 trials

Shared therapeutic areas:

Localized Transitional Cell Cancer of the Renal Pelvis and UreterRecurrent Bladder CancerRecurrent Urethral Cancer+3 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score11%

Robert Montgomery

Fred Hutch/University of Washington Cancer Consortium

Related
6 trials

Shared therapeutic areas:

Hormone-Resistant Prostate CancerStage IIA Prostate CancerStage IIB Prostate Cancer+2 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score9%

Stephen Michael Hahn

Abramson Cancer Center at Penn Medicine

Related
6 trials

Shared therapeutic areas:

Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IIA Prostate Cancer+1 more

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score8%

Stanislaw R. Burzynski, MD, PhD

Burzynski Research Institute

Related
62 trials

Shared therapeutic areas:

Stage IV Prostate CancerAdenocarcinoma of the ProstateRecurrent Prostate Cancer
Similarity Score6%

Jingsong Zhang, M.D., Ph.D.

H. Lee Moffitt Cancer Center and Research Institute

Related
5 trials

Shared therapeutic areas:

Adenocarcinoma of the ProstateStage IV Prostate CancerCancer of Ureter
Similarity Score6%

Saby George

Roswell Park Cancer Institute

Related
6 trials

Shared therapeutic areas:

Stage IV Prostate CancerHormone-Resistant Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Kunle Odunsi

Roswell Park Cancer Institute

Related
5 trials

Shared therapeutic areas:

Hormone-Resistant Prostate CancerStage IV Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score4%

Michael Schweizer

Fred Hutch/University of Washington Cancer Consortium

Related
11 trials

Shared therapeutic areas:

Hormone-Resistant Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Melissa L Abel, M.D.

National Cancer Institute (NCI)

Related
6 trials

Shared therapeutic areas:

Recurrent Prostate Cancer

Worked with same sponsors:

National Cancer Institute (NCI)
Similarity Score2%

Publications (0)

No publications found for this investigator.

Clinical Trials (3)

Showing 3 of 3 trials

NCT01639521Phase 2PrincipalInvestigator

Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer

Anterior Urethral CancerLocalized Transitional Cell Cancer of the Renal Pelvis and UreterPosterior Urethral Cancer+7 more
Withdrawn
NCT01685125Phase 2PrincipalInvestigator

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Hormone-resistant Prostate CancerRecurrent Prostate CancerStage IV Prostate Cancer
Unknown
NCT02237612Not ApplicablePrincipalInvestigator

Diffusion-Weighted MRI in Staging Patients With Localized Prostate Cancer

Adenocarcinoma of the ProstateStage IIA Prostate CancerStage IIB Prostate Cancer
Completed

All 3 trials loaded